Scholar Rock (SRRK) Q3 2025 earnings summary

Executive summary

• Apitegromab's U.S. approval for SMA was delayed due to a Complete Response Letter (CRL) citing only manufacturing compliance at a third-party facility, not efficacy or safety concerns.

• The company completed a Type A meeting with the FDA and Novo Nordisk, with the Catalent Indiana site on track for reinspection by year-end 2025.

• Efforts are underway to add a second U.S.-based fill-finish facility, with commercial capacity secured for Q1 2026.

• The pipeline is advancing, including the phase 2 OPAL study in infants/toddlers and clinical development of SRK-439, a novel myostatin inhibitor.

• The company is also advancing SRK-181 (oncology) and expanding its pipeline.

Financial highlights

• Net loss for Q3 2025 was $102.2 million, up from $64.5 million in Q3 2024.

• Operating expenses for Q3 2025 were $103.6 million, including $18.3 million in non-cash stock-based compensation.

• Cash, cash equivalents, and marketable securities totaled $369.6 million as of September 30, 2025.

• Raised $91.7 million through ATM share sales and $50 million from a debt facility during Q3 2025.

• Equity-based compensation for the nine months was $56.2 million, including $13.0 million in one-time charges related to leadership changes.

Outlook and guidance

• Cash runway expected to fund operations into 2027, including anticipated $60 million from warrants expiring December 2025.

• Anticipates resubmitting the BLA for apitegromab after successful FDA reinspection, targeting U.S. launch in 2026; EMA decision expected by mid-2026.

• Ongoing investment in commercialization infrastructure and pipeline expansion is anticipated.